Recent News

• 09.15.2025 - Stifel Immunology and Inflammation Summit
• 09.08.2025 - Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
• 09.03.2025 - Cantor Global Healthcare Conference
• 08.28.2025 - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
• 08.13.2025 - ARS Pharmaceuticals’ 2Q 2025 Earnings Call
• 08.13.2025 - ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
• 08.04.2025 - ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
• 07.18.2025 - EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Recent Filings

• 08.28.2025 - 8-K Current report
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.21.2025 - 144 Report of proposed sale of securities
• 08.21.2025 - 144 Report of proposed sale of securities
• 08.19.2025 - 144 Report of proposed sale of securities
• 08.13.2025 - EX-99.1 EX-99.1
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - 8-K Current report